Ampio's Ampion reduces osteoarthritis knee pain
This article was originally published in Scrip
Ampio Pharmaceuticals reported statistically significant reductions in pain for patients with osteoarthritis of the knee (OAK) in top-line results from the first of two Phase III clinical trials for the biologic Ampion – an intra-articular injection administered at the site of pain and the company's only new molecular entity (NME) in clinical development.
You may also be interested in...
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.